Abstract:Breast cancer remains the most frequently diagnosed cancer globally, and the metastasis of this malignancy is the primary cause of mortality in breast cancer patients. Hence, prompt diagnosis and timely detection of metastatic breast cancer are critical for effective therapeutic intervention. Both progression and metastasis of this malignancy are closely associated with aberrant expression of specific microRNAs (miRNAs) and enzymes. To facilitate breast cancer diagnosis and concomitant identification of metastatic breast cancer, we have engineered an innovative electrochemiluminescence (ECL)-based sensing platform integrated with enzyme-free DNA amplification circuits for dual functionality. Specifically, microRNA-21 (miR-21) is employed as a biomarker for breast cancer, and miR-21 induces the quenching of the ECL signal from luminophores via a strategically designed catalytic three-hairpin assembly (CTHA) circuit. Subsequently, miR-105 levels are measured via toehold-mediated strand displacement reactions (TSDR). Here, miR-105 restores the initially quenched ECL signal, enabling the assessment of the metastatic propensity. Our experimental data demonstrate that the devised ECL biosensor offers broad linear detection ranges and low detection limits for both miR-21 and miR-105. Importantly, our novel platform was also successfully validated by using cellular and serum samples. This biosensor not only discriminates breast cancer cell lines MCF-7 and MDA-MB-231 from nonbreast cancer cells like HepG2, TPC-1, and HeLa, but it also distinguishes between malignant MCF-7 and metastatic MDA-MB-231 cells. Consequently, our novel approach holds significant promise for clinical applications and precise cancer screening.

Metastatic Cell Detection Using A Phage-Peptide-Modified Light-Addressable Potentiometric Sensor

Label-Free Biosensor: A Novel Phage-Modified Light Addressable Potentiometric Sensor System for Cancer Cell Monitoring

Peptide-based Method for Detection of Metastatic Transformation in Primary Tumors of Breast Cancer.

An Electrochemical Biosensor Based on Electroactive Peptide Nanoprobes for the Sensitive Analysis of Tumor Cells.

A Label-Free Electrochemical Impedance Cytosensor Based on Specific Peptide-Fused Phage Selected from Landscape Phage Library

Phage Biosensor for the Classification of Metastatic Urological Cancers from Urine

In vitro selection of DNA aptamers for metastatic breast cancer cell recognition and tissue imaging.

Label-free Biosensor for Non-Invasive and Low-Cost Detection of Metastatic Risk Through Urine Biopsy

Screening and identification of a specific peptide binding to breast cancer cells from a phage-displayed peptide library

Electrochemical Aptasensor for Ultralow Fouling Cancer Cell Quantification in Complex Biological Media Based on Designed Branched Peptides

Label-free and high-sensitive detection of human breast cancer cells by aptamer-based leaky surface acoustic wave biosensor array

The Cell Detection Using EIS Sensor and Phage Display

Monitoring the Progression of Metastatic Breast Cancer on Nanoporous Silica Chips

Recombinant peptide-based biosensing approaches for targeting breast cancer-derived exosomes

Precise and Label-Free Tumour Cell Recognition Based on a Black Phosphorus Nanoquenching Platform.

Detection of Circulating Tumor Cells in Breast Cancer Patients by Nanopore Sensing with Aptamer-Mediated Amplification

Data from Real-time in Vivo Molecular Detection of Primary Tumors and Metastases with Ratiometric Activatable Cell-Penetrating Peptides

A Novel Cytosensor for Capture, Detection and Release of Breast Cancer Cells Based on Metal Organic Framework PCN-224 and DNA Tetrahedron Linked Dual-Aptamer

Dual-microRNA-Controlled Electrochemiluminescence Biosensor for Breast Cancer Diagnosis and Supplemental Identification of Breast Cancer Metastasis.

Application of functional peptides in the electrochemical and optical biosensing of cancer biomarkers

Identifying a Membrane-Type 2 Matrix Metalloproteinase-Targeting Peptide for Human Lung Cancer Detection and Targeting Chemotherapy with Functionalized Mesoporous Silica